Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research

Up-regulation expression and prognostic significance of Syntaxin4 in kidney renal clear cell carcinoma

Authors: Lishan He, Huiming Jiang, Zhenqiang Lai, Zhixiong Zhong, Zhanqin Huang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Syntaxin4 (STX4) gene encodes the protein STX4, a member of soluble N-ethylmaleimide-sensitive factor attachment protein receptors protein, playing a vital role in cell invadopodium formation and invasion, which is associated with the malignant progression of various human cancers. However, the expression and prognostic significance of STX4 in kidney renal clear cell carcinoma (KIRC) remain to be investigated.

Methods

In this study, we collected the mRNA expression of STX4 in 535 KIRC patients from The Cancer Genome Atlasthrough the University of California Santa Cruz Xena database platform. Then we explored the expression of STX4 in KIRC, and the relationship with clinicopathological characteristics and prognostic value. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes function enrichment analyses were used to explore the potential mechanism of STX4 in KIRC. qRT-PCR analysis was performed toverify the above results with real world tissue specimens.

Results

The results indicated that STX4 was up-expressed in KIRC, and were associated with higher histological grade, advanced stage, and poorer prognosis. Moreover, elevated STX4 expression is an independent risk factor for KIRC. qRT-PCR analysis showed that STX4 was significantly elevated in 10 paired of KIRC samples compared to normal samples. Functional enrichment analysis indicated that endo/exocytosis, autophagy, mTOR signaling pathway, and NOD-like receptor signaling pathway were enriched.

Conclusions

In summary, STX4 is constantly up-expressed in KIRC tissues, associated with a poor prognosis. We suggest that it can be an effective biomarker for the prognosis of KIRC and may be a novel therapeutic target in KIRC.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. https://doi.org/10.1016/j.eururo.2015.01.005.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179–84.PubMed

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009. https://doi.org/10.1038/nrdp.2017.9.CrossRefPubMedPubMedCentral

Mitsui Y, Shiina H, Kato T, Maekawa S, Hashimoto Y, Shiina M, et al. Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma. Mol Cancer Res. 2017;15(7):884–95. https://doi.org/10.1158/1541-7786.MCR-16-0444.CrossRefPubMedPubMedCentral

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. National comprehensive cancer network. Kidney cancer, version 3. 2015. J Natl Compr Cancer Netw. 2015;13(2):151–9. https://doi.org/10.6004/jnccn.2015.0022.CrossRef

Stephens DC, Harris DA. Organizing 'Elements': facilitating exocytosis and promoting metastasis. Trends Cancer. 2020;6(4):273–6. https://doi.org/10.1016/j.trecan.2020.01.020.CrossRefPubMed

Chen YA, Scheller RH. SNARE-mediated membrane fusion. Nat Rev Mol Cell Biol. 2001;2(2):98–106. https://doi.org/10.1038/35052017.CrossRefPubMed

Miyata T, Ohnishi H, Suzuki J, Yoshikumi Y, Ohno H, Mashima H, et al. Involvement of syntaxin 4 in the transport of membrane-type 1 matrix metalloproteinase to the plasma membrane in human gastric epithelial cells. Biochem Biophys Res Commun. 2004;323(1):118–24. https://doi.org/10.1016/j.bbrc.2004.08.064.CrossRefPubMed

10.

Brasher MI, Martynowicz DM, Grafinger OR, Hucik A, Shanks-Skinner E, Uniacke J, et al. Interaction of Munc18c and syntaxin4 facilitates invadopodium formation and extracellular matrix invasion of tumor cells. J Biol Chem. 2017;292(39):16199–210. https://doi.org/10.1074/jbc.M117.807438.CrossRefPubMedPubMedCentral

11.

Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39:W316–22.CrossRef

12.

Nuyanzina VA, Nabokina SM. Identification of exocytosis mediator proteins in peripheral blood neutrophils of patients with chronic myeloid leukemia. Bull Exp Biol Med. 2004;137(4):361–3. https://doi.org/10.1023/B:BEBM.0000035130.80245.13.CrossRefPubMed

13.

Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, et al. Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis. 2014;5(11):e1528. https://doi.org/10.1038/cddis.2014.489.CrossRefPubMedPubMedCentral

14.

Hagiwara N, Kadono N, Miyazaki T, Maekubo K, Hirai Y. Extracellular syntaxin4 triggers the differentiation program in teratocarcinoma F9 cells that impacts cell adhesion properties. Cell Tissue Res. 2013;354(2):581–91. https://doi.org/10.1007/s00441-013-1680-0.CrossRefPubMed

15.

Lanzetti L, Di Fiore PP. Behind the scenes: Endo/exocytosis in the Acquisition of Metastatic Traits. Cancer Res. 2017;77(8):1813–7. https://doi.org/10.1158/0008-5472.CAN-16-3403.CrossRefPubMed

16.

Kennedy MJ, Davison IG, Robinson CG, Ehlers MD. Syntaxin-4 defines a domain for activity-dependent exocytosis in dendritic spines. Cell. 2010;141(3):524–35. https://doi.org/10.1016/j.cell.2010.02.042.CrossRefPubMedPubMedCentral

17.

Mohanasundaram P, Shanmugam MM. Role of syntaxin 4 in activity-dependent exocytosis and synaptic plasticity in hippocampal neurons. Sci Signal. 2010;3:jc7.CrossRef

18.

Williams KC, McNeilly RE, Coppolino MG. SNAP23, Syntaxin4, and vesicle-associated membrane protein 7 (VAMP7) mediate trafficking of membrane type 1-matrix metalloproteinase (MT1-MMP) during invadopodium formation and tumor cell invasion. Mol Biol Cell. 2014;25(13):2061–70. https://doi.org/10.1091/mbc.e13-10-0582.CrossRefPubMedPubMedCentral

19.

Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42. https://doi.org/10.1038/nrc.2017.53.CrossRefPubMed

20.

Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25–32.CrossRef

21.

Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57(1):5–14. https://doi.org/10.3349/ymj.2016.57.1.5.CrossRefPubMed

22.

Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immun. 2010;11(1):55–62. https://doi.org/10.1038/ni.1823.CrossRef

23.

Dolai S, Liang T, Orabi AI, Holmyard D, Xie L, Greitzer-Antes D, et al. Pancreatitis-induced depletion of Syntaxin 2 promotes autophagy and increases Basolateral exocytosis. Gastroenterology. 2018;154:1805–1821.e5.CrossRef

Title: Up-regulation expression and prognostic significance of Syntaxin4 in kidney renal clear cell carcinoma
Authors: Lishan He
Huiming Jiang
Zhenqiang Lai
Zhixiong Zhong
Zhanqin Huang
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08736-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

GNA14 stimulation of KLF7 promotes malignant growth of endometrial cancer through upregulation of HAS2

The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma

Correction to: TRAP1 suppresses oral squamous cell carcinoma progression by reducing oxidative phosphorylation metabolism of Cancer-associated fibroblasts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer